

- **Full Name:** Dr. Joe Yeong, MBBS, PhD, Mmed (Pathology)
- **Current Position & Affiliation:** Group Leader
*Institute of Molecular and Cell Biology (IMCB, A*STAR, Singapore)*
Department of Anatomical Pathology, Singapore General Hospital (SGH).
- **Country:** Singapore

• Educational Background:

1. Bachelor of Medicine, Bachelor of Surgery (MBBS, Fudan University, 2009)
2. PhD (Cancer Immunology, Integrative Science & Engineering, National University of Singapore, 2014)
3. Royal College of Pathologist (British) Associateship (2016)
4. Master of Medicine (Pathology), University of Western Sydney (2019)

• Professional Experience:

Dr. Joe Yeong's main research focus is to understand and overcome the resistance of immune checkpoint blockade immunotherapy. As an immuno-pathologist, his key vision is to bridge between immunologists and pathologists to better harness the advances of immunotherapy and further beyond. He is the pioneer in the automation of quantitative multiplex immunohistochemistry, using clinical autostainers to study and quantitate the tumour immune microenvironment in clinical samples, and has published >100 papers in this field. His works on cancer immunology are included in multiple National Medical Research Council funded studies as well as pharmaceutical industry sponsored projects (>13 million dollars since 2017). He also served as a committee member in the World Immunotherapy Council, Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019 & 2023 WIC Global Symposium as well as the multiplex IF Expert Consensus Meeting 2022. He also serves as Program Chair of one of the largest AI medical Imaging conferences, CLINICCAI-MICCAI. He has an editorial role in Elsevier (Immunoinformatics), SLAS Technology (Journal), Frontiers, World Scientific (Chief Editor) and Pathogens. He also serves as the Secretary (Executive) at the Singapore Society of Oncology – Cancer Immunotherapy Consortium, and is the Co-lead in Education/Diagnostic of Singhealth Duke-NUS Cell Therapy Centre as well as Advisor (Spatial Technology) of Cancer Discovery Hub, National Cancer Centre.

• Professional Organizations:

1. Group Leader (Institute of Molecular and Cell Biology, A*STAR)
2. Principal Investigator in Anatomical pathology (Singapore General Hospital)
3. Asst Professor Duke-NUS Medical School (Pathology Academic Clinical Program)
4. Advisor (Spatial Tech-Cancer Discovery Hub) National Cancer Centre Singapore
5. Visiting Assoc. Professor (Dept. of Surgery, Faculty of Medicine, University of Malaya)
6. Principal Associate (Cancer Science Institute of Singapore, NUS)
7. Visiting Fellow (Western Sydney University, Dept. of Pathology, Liverpool Hospital, Australia)
8. Executive secretary, Singapore Society of Oncology – Cancer Immunotherapy Consortium
9. Education/Diagnostic Co-Lead, SingHealth Duke-NUS Cell Therapy Centre

• Main Scientific Publications:

Cheung et al., Residual SARS-CoV-2 viral antigens detected in gastrointestinal and hepatic tissues from five recovered COVID-19 patients. *GUT* 2021 (Corresponding author)

Goh, et al. A comparison between non-pulmonary and pulmonary immune responses in a HIV decedent who succumbed to COVID-19. *GUT*, 2021(Corresponding author)

Ng H, et al. Immunohistochemical scoring of CD38 in the tumour microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. *J Immunother Cancer*. 2020;8(2):e000987. (Corresponding author).

Leong, et al. Leveraging advances in immunopathology and artificial intelligence to analyze in vitro tumor models in composition and space. *Adv Drug Deliv Rev* 2021. (Corresponding author)

Yang et al. SC-MEB: spatial clustering with hidden Markov random field using empirical Bayes. *Briefings in Bioinformatics* 2021 (Corresponding author)

Yeong J, Fox B, A. Sater. H, A, Rodriguez-Canaes, J. A., Mckee T. D. (2022) Multiplex Immunohistochemistry/Immunofluorescence Technique: The Potential and Promise for Clinical Application. Lausanne. *Frontiers Media SA*. Doi: 10.3389/978-2-88974-718-4

Yeong J, Suteja L, Intra-tumoral CD39+CD8+ T cells predict response to PD-1/PD-L1 blockade in patients with NSCLC, *JTO* 2021 JIF: 13.357 15.

Nerurkar SN, Goh D, Cheung CCL, Nga PQY, Lim JCT, Yeong JPS. Transcriptional Spatial Profiling of Cancer Tissues in the Era of Immunotherapy: The Potential and Promise. *Cancers*. 2020;12(9). (Corresponding author)

Tan, W.C.C., et al. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. *Cancer Commun (Lond)* 40, 135-153 (2020). (Correspondent author)